Étude de réponse histologique du cancer du sein HER2+ après chimiothérapie néoadjuvante associant taxane et trastuzumab

Gynecologie Obstetrique & Fertilite Pub Date : 2016-07-01 DOI:10.1016/j.gyobfe.2016.06.007

L. Komguem , P. Guilbert , M. Doublier , F. Guillemin

{"title":"Étude de réponse histologique du cancer du sein HER2+ après chimiothérapie néoadjuvante associant taxane et trastuzumab","authors":"L. Komguem , P. Guilbert , M. Doublier , F. Guillemin","doi":"10.1016/j.gyobfe.2016.06.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>In our study, we aimed to assess the pathologic complete response after neo-additive chemotherapy that contains a taxan associated to trastuzumab for patients treated from breast cancer at the institute Jean-Godinot between 2012 and 2014, and to evaluate factors associated to this pathologic complete response.</p></div><div><h3>Methods</h3><p>Retrospective study with clinical, anatomopathologic and radiologic parameters analysis before and after new adjuvant chemotherapy. The statistical analysis was done on <em>logiciel</em> XL-STAT, the Mann-Whitney-Wilcoxon for quantitative variables and Fisher exact tests for qualitative variables, the Spearman rang test.</p></div><div><h3>Results</h3><p>The rate of pathologic complete response is 38.8%. The prognostic factor associated to pathologic complete response is a Ki-67>44%.</p></div><div><h3>Conclusion</h3><p>The pathologic complete response rate corresponds to international lower rate; because of the lack of several data, we found out only one prognostic factor, Ki-67>44%.</p></div>","PeriodicalId":55077,"journal":{"name":"Gynecologie Obstetrique & Fertilite","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.gyobfe.2016.06.007","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecologie Obstetrique & Fertilite","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1297958916301692","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

Abstract

Objectives

In our study, we aimed to assess the pathologic complete response after neo-additive chemotherapy that contains a taxan associated to trastuzumab for patients treated from breast cancer at the institute Jean-Godinot between 2012 and 2014, and to evaluate factors associated to this pathologic complete response.

Methods

Retrospective study with clinical, anatomopathologic and radiologic parameters analysis before and after new adjuvant chemotherapy. The statistical analysis was done on logiciel XL-STAT, the Mann-Whitney-Wilcoxon for quantitative variables and Fisher exact tests for qualitative variables, the Spearman rang test.

Results

The rate of pathologic complete response is 38.8%. The prognostic factor associated to pathologic complete response is a Ki-67 > 44%.

Conclusion

The pathologic complete response rate corresponds to international lower rate; because of the lack of several data, we found out only one prognostic factor, Ki-67 > 44%.

查看原文本刊更多论文

紫杉烷和曲妥珠单抗新辅助化疗后HER2+乳腺癌的组织学反应研究

在我们的研究中，我们旨在评估2012年至2014年间Jean-Godinot研究所乳腺癌患者接受含有曲妥珠单抗相关taxan的新添加性化疗后的病理完全缓解，并评估与该病理完全缓解相关的因素。方法回顾性分析新辅助化疗前后的临床、解剖病理及影像学参数。统计分析采用logiciel XL-STAT，定量变量采用Mann-Whitney-Wilcoxon检验，定性变量采用Fisher精确检验，Spearman区间检验。结果病理完全缓解率为38.8%。与病理完全缓解相关的预后因素是Ki-67;44%。结论病理完全缓解率符合国际较低水平;由于缺乏一些数据，我们只发现了一个预后因素Ki-67 >44%。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gynecologie Obstetrique & Fertilite 医学-妇产科学

CiteScore

0.90

自引率

0.00%

发文量

审稿时长

4-8 weeks